Brian R. Adams J.D.
Net Worth

Last updated:

What is Brian R. Adams J.D. net worth?

The estimated net worth of Mr. Brian R. Adams J.D. is at least $4,707,174 as of 27 Jun 2024. He owns shares worth $1,106,605 as insider, has earned $760,319 from insider trading and has received compensation worth at least $2,840,250 in Relay Therapeutics, Inc..

What is the salary of Brian R. Adams J.D.?

Mr. Brian R. Adams J.D. salary is $568,050 per year as Gen. Counsel & Sec. in Relay Therapeutics, Inc..

How old is Brian R. Adams J.D.?

Mr. Brian R. Adams J.D. is 51 years old, born in 1974.

What stocks does Brian R. Adams J.D. currently own?

As insider, Mr. Brian R. Adams J.D. owns shares in one company:

Company Title Shares Price per share Total value
Relay Therapeutics, Inc. (RLAY) Gen. Counsel & Sec. 325,472 $3.4 $1,106,605

What does Relay Therapeutics, Inc. do?

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Brian R. Adams J.D. insider trading

Relay Therapeutics, Inc.

Mr. Brian R. Adams J.D. has made 29 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 295 units of RLAY stock worth $1,847 on 27 Jun 2024.

The largest trade he's ever made was exercising 10,000 units of RLAY stock on 20 Jul 2020. As of 27 Jun 2024 he still owns at least 325,472 units of RLAY stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 295 $6.26 $1,847
Sale
Common Stock 1,623 $6.38 $10,355
Sale
Common Stock 348 $7.7 $2,680
Sale
Common Stock 1,929 $9.64 $18,596
Sale
Common Stock 294 $11.51 $3,384
Sale
Common Stock 1,632 $6.03 $9,841
Sale
Common Stock 294 $8.38 $2,464
Sale
Common Stock 1,628 $11.8 $19,210
Sale
Common Stock 294 $12.12 $3,563
Sale
Common Stock 863 $11.16 $9,631
Sale
Common Stock 347 $15.36 $5,330
Sale
Common Stock 864 $21.56 $18,628
Sale
Common Stock 9,994 $20 $199,880
Sale
Common Stock 295 $14.49 $4,275
Sale
Common Stock 728 $21.54 $15,681
Sale
Common Stock 294 $22.73 $6,683
Sale
Common Stock 734 $21.27 $15,612
Sale
Common Stock 300 $20.31 $6,093
Sale
Common Stock 708 $25.57 $18,104
Sale
Common Stock 333 $29.87 $9,947
Sale
Common Stock 295 $33.1 $9,765
Sale
Common Stock 6,500 $35.42 $230,230
Option
Common Stock 6,500 $4.12 $26,780
Option
Stock Option (Right to Buy) 6,500 $4.12 $26,780
Sale
Common Stock 293 $36.87 $10,803
Sale
Common Stock 6,500 $4.12 $26,780
Sale
Stock Option (Right to Buy) 6,500 $4.12 $26,780
Option
Stock Option (Right to Buy) 6,500 $4.12 $26,780
Option
Stock Option (Right to Buy) 6,500 $4.12 $26,780
Option
Common Stock 6,500 $35.02 $227,630
Sale
Common Stock 293 N/A N/A
Sale
Common Stock 6,500 $4.12 $26,780
Option
Stock Option (Right to Buy) 6,500 $4.12 $26,780
Option
Common Stock 6,500 $4.12 $26,780
Sale
Common Stock 6,500 $4.12 $26,780
Option
Common Stock 6,500 $4.12 $26,780
Option
Stock Option (Right to Buy) 6,500 $4.12 $26,780
Option
Stock Option (Right to Buy) 5,000 $4.12 $20,600
Option
Common Stock 5,000 $4.12 $20,600
Sale
Common Stock 5,000 $4.12 $20,600
Purchase
Common Stock 10,000 $20 $200,000

Relay Therapeutics key executives

Relay Therapeutics, Inc. executives and other stock owners filed with the SEC: